---
document_datetime: 2025-12-09 23:24:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mysildecard.html
document_name: mysildecard.html
version: success
processing_time: 0.1281885
conversion_datetime: 2025-12-25 02:55:52.781624
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mysildecard

[RSS](/en/individual-human-medicine.xml/66387)

##### Authorised

This medicine is authorised for use in the European Union

sildenafil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Mysildecard](#more-information-on-mysildecard-1298)
- [Related information](#related-information-687)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Mysildecard. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mysildecard.

For practical information about using Mysildecard, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Mysildecard and what is it used for?

Mysildecard is a medicine used to treat adults and children from 1 year of age with pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries of the lungs). In adults, it is used in patients with class II (slight limitation of physical activity) or class III (marked limitation of physical activity) PAH.

Mysildecard contains the active substance sildenafil. It is a 'generic medicine'. This means that Mysildecard is similar to a 'reference medicine' already authorised in the European Union (EU) called Revatio.

## How is Mysildecard used?

Mysildecard can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH.

Mysildecard is available as tablets (20 mg). In adults, Mysildecard is taken at a dose of 20 mg three times a day. Lower doses of Mysildecard may be needed in patients taking some medicines that affect the way Mysildecard is broken down in the body.

In children aged one to 17, the recommended dose is 20 mg three times a day in those over 20 kg. Higher doses should not be used. In children weighing less than 20 kg the maximum recommended dose would be 10 mg three times a day but Mysildecard can only be used when a 20 mg dose is to be given. For lower doses, other medicines containing sildenafil should therefore be used.

## How does Mysildecard work?

PAH is a debilitating disease where there is severe constriction (narrowing) of the blood vessels of the lungs. This leads to high blood pressure in the vessels taking blood from the heart to the lungs and reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. The active substance in Mysildecard, sildenafil, belongs to a group of medicines called 'phosphodiesterase-type-5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme. This enzyme is found in the blood vessels of the lungs. When it is blocked, a substance called 'cyclic guanine monophosphate' (cGMP) cannot be broken down, so that it remains in the vessels where it causes relaxation and widening of the blood vessels. In patients with PAH, sildenafil widens the blood vessels of the lungs, which lowers the blood pressure and improves symptoms.

## How has Mysildecard been studied?

Because the effectiveness and safety of sildenafil in PAH is already well established, studies in people have been limited to tests to determine that it is bioequivalent to another authorised sildenafil-containing tablet. Two medicines are bioequivalent when they produce the same levels of the active substance in the body. In this case Mysildecard was not compared with the reference product Revatio, but with Viagra. This was considered acceptable since Revatio and Viagra have the same qualitative composition and are made in the same way by the same manufacturer.

## What are the benefits and risks of Mysildecard?

Because Mysildecard is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Mysildecard approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Mysildecard was considered to be comparable to Revatio. Therefore, the CHMP's view was that as for Revatio the benefit of Mysildecard outweighs the identified risks. The Committee recommended that Mysildecard be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mysildecard?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mysildecard have been included in the summary of product characteristics and the package leaflet.

## Other information about Mysildecard

The European Commission granted a marketing authorisation valid throughout the European Union for Mysildecard on 15 September 2016.

For more information about treatment with Mysildecard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Mysildecard : EPAR - Summary for the public

Reference Number: EMA/513094/2016

English (EN) (86.18 KB - PDF)

**First published:** 08/12/2016

**Last updated:** 08/12/2016

[View](/en/documents/overview/mysildecard-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-899)

български (BG) (119.77 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/bg/documents/overview/mysildecard-epar-summary-public_bg.pdf)

español (ES) (91.77 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/es/documents/overview/mysildecard-epar-summary-public_es.pdf)

čeština (CS) (116.3 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/cs/documents/overview/mysildecard-epar-summary-public_cs.pdf)

dansk (DA) (91.22 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/da/documents/overview/mysildecard-epar-summary-public_da.pdf)

Deutsch (DE) (92.52 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/de/documents/overview/mysildecard-epar-summary-public_de.pdf)

eesti keel (ET) (89.92 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/et/documents/overview/mysildecard-epar-summary-public_et.pdf)

ελληνικά (EL) (121.07 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/el/documents/overview/mysildecard-epar-summary-public_el.pdf)

français (FR) (92.57 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/fr/documents/overview/mysildecard-epar-summary-public_fr.pdf)

hrvatski (HR) (110.78 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/hr/documents/overview/mysildecard-epar-summary-public_hr.pdf)

italiano (IT) (91.29 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/it/documents/overview/mysildecard-epar-summary-public_it.pdf)

latviešu valoda (LV) (112.46 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/lv/documents/overview/mysildecard-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (114.38 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/lt/documents/overview/mysildecard-epar-summary-public_lt.pdf)

magyar (HU) (110.91 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/hu/documents/overview/mysildecard-epar-summary-public_hu.pdf)

Malti (MT) (116.93 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/mt/documents/overview/mysildecard-epar-summary-public_mt.pdf)

Nederlands (NL) (91.63 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/nl/documents/overview/mysildecard-epar-summary-public_nl.pdf)

polski (PL) (117.83 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/pl/documents/overview/mysildecard-epar-summary-public_pl.pdf)

português (PT) (91.98 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/pt/documents/overview/mysildecard-epar-summary-public_pt.pdf)

română (RO) (113.19 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/ro/documents/overview/mysildecard-epar-summary-public_ro.pdf)

slovenčina (SK) (115.8 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sk/documents/overview/mysildecard-epar-summary-public_sk.pdf)

slovenščina (SL) (109.88 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sl/documents/overview/mysildecard-epar-summary-public_sl.pdf)

Suomi (FI) (91.16 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/fi/documents/overview/mysildecard-epar-summary-public_fi.pdf)

svenska (SV) (92.13 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sv/documents/overview/mysildecard-epar-summary-public_sv.pdf)

Mysildecard : EPAR - Risk-management-plan summary

English (EN) (302.25 KB - PDF)

**First published:** 15/01/2025

[View](/en/documents/rmp-summary/mysildecard-epar-risk-management-plan-summary_en.pdf)

## Product information

Mysildecard : EPAR - Product Information

English (EN) (442.66 KB - PDF)

**First published:** 08/12/2016

**Last updated:** 02/12/2025

[View](/en/documents/product-information/mysildecard-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-163)

български (BG) (555.68 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/bg/documents/product-information/mysildecard-epar-product-information_bg.pdf)

español (ES) (446.4 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/es/documents/product-information/mysildecard-epar-product-information_es.pdf)

čeština (CS) (393.76 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/cs/documents/product-information/mysildecard-epar-product-information_cs.pdf)

dansk (DA) (493.73 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/da/documents/product-information/mysildecard-epar-product-information_da.pdf)

Deutsch (DE) (392.66 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/de/documents/product-information/mysildecard-epar-product-information_de.pdf)

eesti keel (ET) (422.81 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/et/documents/product-information/mysildecard-epar-product-information_et.pdf)

ελληνικά (EL) (421.01 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/el/documents/product-information/mysildecard-epar-product-information_el.pdf)

français (FR) (413.36 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/fr/documents/product-information/mysildecard-epar-product-information_fr.pdf)

hrvatski (HR) (504.93 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/hr/documents/product-information/mysildecard-epar-product-information_hr.pdf)

íslenska (IS) (489.33 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/is/documents/product-information/mysildecard-epar-product-information_is.pdf)

italiano (IT) (502.4 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/it/documents/product-information/mysildecard-epar-product-information_it.pdf)

latviešu valoda (LV) (348.99 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/lv/documents/product-information/mysildecard-epar-product-information_lv.pdf)

lietuvių kalba (LT) (416.76 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/lt/documents/product-information/mysildecard-epar-product-information_lt.pdf)

magyar (HU) (539.58 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/hu/documents/product-information/mysildecard-epar-product-information_hu.pdf)

Malti (MT) (684.66 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/mt/documents/product-information/mysildecard-epar-product-information_mt.pdf)

Nederlands (NL) (478.12 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/nl/documents/product-information/mysildecard-epar-product-information_nl.pdf)

norsk (NO) (358.26 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/no/documents/product-information/mysildecard-epar-product-information_no.pdf)

polski (PL) (391.58 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/pl/documents/product-information/mysildecard-epar-product-information_pl.pdf)

português (PT) (376.29 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/pt/documents/product-information/mysildecard-epar-product-information_pt.pdf)

română (RO) (439.28 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/ro/documents/product-information/mysildecard-epar-product-information_ro.pdf)

slovenčina (SK) (522.33 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/sk/documents/product-information/mysildecard-epar-product-information_sk.pdf)

slovenščina (SL) (358.94 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/sl/documents/product-information/mysildecard-epar-product-information_sl.pdf)

Suomi (FI) (374.01 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/fi/documents/product-information/mysildecard-epar-product-information_fi.pdf)

svenska (SV) (354.18 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

02/12/2025

[View](/sv/documents/product-information/mysildecard-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000314981 02/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mysildecard : EPAR - All Authorised presentations

English (EN) (42.32 KB - PDF)

**First published:** 08/12/2016

**Last updated:** 08/12/2016

[View](/en/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-385)

български (BG) (48.89 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/bg/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_bg.pdf)

español (ES) (42.37 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/es/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.84 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/cs/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.45 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/da/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (43.32 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/de/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.85 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/et/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.16 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/el/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_el.pdf)

français (FR) (45.16 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/fr/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.64 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/hr/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.49 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/is/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.09 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/it/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.08 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/lv/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.66 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/lt/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.21 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/hu/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (46.38 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/mt/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.28 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/nl/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.37 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/no/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.89 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/pl/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.32 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/pt/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_pt.pdf)

română (RO) (44.92 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/ro/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.34 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sk/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.83 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sl/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (42.59 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/fi/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (41.27 KB - PDF)

**First published:**

08/12/2016

**Last updated:**

08/12/2016

[View](/sv/documents/all-authorised-presentations/mysildecard-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mysildecard International non-proprietary name (INN) or common name sildenafil Therapeutic area (MeSH) Hypertension, Pulmonary Anatomical therapeutic chemical (ATC) code G04BE03

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

**Adults**

**Paediatric population** Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004186

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 21/07/2016 Marketing authorisation issued 15/09/2016 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mysildecard : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.65 KB - PDF)

**First published:** 21/05/2024

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/mysildecard-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mysildecard : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (158.51 KB - PDF)

**First published:** 16/08/2019

**Last updated:** 21/05/2024

[View](/en/documents/procedural-steps-after/mysildecard-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Mysildecard : EPAR - Public assessment report

Adopted

Reference Number: EMA/533666/2016

English (EN) (249.78 KB - PDF)

**First published:** 08/12/2016

**Last updated:** 08/12/2016

[View](/en/documents/assessment-report/mysildecard-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mysildecard

Adopted

Reference Number: EMA/485582/2016

English (EN) (75.87 KB - PDF)

**First published:** 03/08/2016

**Last updated:** 03/08/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mysildecard_en.pdf)

#### More information on Mysildecard

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-517)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0041860000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)